Bogle Investment Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bogle Investment Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-41,445	Closed	-$4.57M	–	272
2020 Q2	$4.57M	Sell	41,445 -50,142	-55%	-$5.54M	0.76%	32
2020 Q1	$9.13M	Sell	91,587 -8,777	-9%	-$1.13M	0.95%	47
2019 Q4	$15M	Sell	100,364 -5,867	-6%	-$798K	1.4%	2
2019 Q3	$13.6M	Sell	106,231 -1,778	-2%	-$238K	1.17%	12
2019 Q2	$15.4M	Hold	108,009	–	–	1.21%	8
2019 Q1	$15.4M	Buy	108,009 +39,185	+57%	+$5.11M	1.18%	6
2018 Q4	$8.53M	Buy	68,824 +22,168	+48%	+$3.29M	0.67%	64
2018 Q3	$7.84M	Sell	46,656 -8,911	-16%	-$1.53M	0.56%	73
2018 Q2	$9.57M	Buy	+55,567	New	+$9.08M	0.69%	68
2014 Q2	–	Sell	-74,250	Closed	-$10.3M	–	354
2014 Q1	$10.3M	Buy	+74,250	New	+$11.2M	0.71%	45

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Bogle Investment Management's JAZZ Position: Q3 2020 in Review

Bogle Investment Management sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2020, closing a stake of 41,445 shares — an estimated $4.57M sold.

Bogle Investment Management first reported a position in JAZZ in Q1 2014 and held it in 10 quarters. The position peaked at $15.4M in Q1 2019. 390 funds tracked by Wall St. Rank hold JAZZ as of Q3 2020.

Bogle Investment Management reported no remaining Jazz Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Bogle Investment Management sold 41,445 Jazz Pharmaceuticals shares in Q3 2020, an estimated $4.57M.
Bogle Investment Management first reported a position in Jazz Pharmaceuticals in Q1 2014 and held it in 10 quarters.
Bogle Investment Management's Jazz Pharmaceuticals position peaked at $15.4M in Q1 2019.
390 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2020.

Based on Bogle Investment Management's 13F filing for Q3 2020, filed 12 Nov 2020.